GHP Noetic Science-Psychedelic Pharma Inc. (GHP) and Diamond Therapeutics Inc. (Diamond) announced the signing of a letter of intent dated effective February 2, 2021. The LOI sets out the general terms and conditions pursuant to which GHP has agreed to acquire all of the issued and outstanding securities of Diamond in exchange for securities of GHP. It is anticipated that, at the Closing, all current officers and directors of GHP will resign and be replaced by nominees of Diamond, which are expected to include: Judith Blumstock - Chief Executive Officer and Director. William Hilson - Executive Chair. Richard Boadway - Lead Independent Director. Peter Pekos - Director.